1. Chen, Y.J.*, Chen, C. & Wu, X.R. Dicarbonyl reduction by single enzyme for the preparation of chiral diols. Chem. Soc. Rev. 2012, 41(5), 1742-1753.
2. Dacol E.C., Wang S.Z., Chen Y.J.* & Lepique A.P.* The interaction of SET and protein phosphatase 2A as target for cancer therapy. Biochim. Biophys. Acta Rev. Cancer 2021, 1876(1), 188578.
3. Wu, X.R., Jiang, J.P. & Chen, Y.J.* Correlation between intracellular cofactor concentrations and biocatalytic efficiency: coexpression of diketoreductase and glucose dehydrogenase for the preparation of chiral diol for statin drugs. ACS Catal. 2011, 1 (12), 1661-1664.
4. Zhang, J.L., Tao, S.S., Zhang, B.J., Wu, X.R & Chen, Y.J.* Microparticle-based strategy for controlled release of substrate for the biocatalytic preparation of L-homophenylalanine. ACS Catal. 2014, 4(5), 1584-1587.
5. Gu, Y.Y., Wu, X.R., Liu, H. & Chen, Y.J.* Photoswitchable heparinase III for enzymatic preparation of low molecular weight heparin. Org. Lett. 2018, 20(1), 48-51.
6. Yang, J., Chen, Z.M., Liu, N. & Chen, Y.J.* Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. Redox Biol. 2018, 19(1), 158-165.
7. Tan Y.Z., Wang M, & Chen Y.J.* Reprogramming the biosynthesis of precursor peptide to create a selenazole-containing nosiheptide analogue. ACS Synth. Biol. 2022, 11(1), 85-91.
8. Wang K, Chen S.Y., Wu Y, Wang Y, Lu Y., Sun Y.Z. & Chen Y.J.*, The ufmylation modification of ribosomal protein L10 in the development of pancreatic adenocarcinoma. Cell Death Dis. 2023, 14(6), 350-358.
9. Zhang B, Jin W.Z., Zhang Y.Y., Dai Y, Li H.H., Sun Y.Z., Wu X.R.*, Luo J.* & Chen Y.J.*, A type I/type III PKS hybrid generates cinnamomycin A-D. Org. Lett. 2023, 25(15), 2560-2564.
10. Zhao, M.Y., Dai, B.Y., Li, X.D., Zhang, Y.X., Qiao, C., Qin, Y., Li, Z., Li, Q.M., Wang, S.Z.*, Yang, Y.* & Chen, Y.J.*, RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia. eLife, 2023, https://doi.org/10.1101/2023.05.24.542110.
1. 国家重点研发计划“合成生物学”重点专项项目：基于成药性特征的微生物天然产物合成生物学创制（No.2018YFA0902000，2019.07－2024.06）
2. 药物生物合成和生物转化学科创新引智基地（No. BP1221007，2022.01-2025.12）
3.“重大新药创制”国家科技重大专项“十一五”项目： 抗肿瘤分子靶向候选药物TGI-1002 的研究（2009.01－2010.12，No.2009ZX09103-089）；
4.“重大新药创制”国家科技重大专项“十二五”项目：抗耐药结核杆菌1类新药诺卡沙星注射剂的研究（2012.01－2015.12，No.2012ZX09103-101-030）；
5.“重大新药创制”国家科技重大专项“十三五”项目：硫肽类抗生素成药性关键技术和注射用硫肽环素临床前研究（2019.01－2020.12，No.2018ZX09721001-004-001）
6. 国家自然科学基金重大研究计划培育项目：转录因子QM的磷酸化过程与炎癌转化关系的研究（2013.01－2015.12，No.91229116）
7. 国家自然科学基金面上项目：采用前体肽基因置换策略定向生物合成新颖诺卡沙星衍生物（2012.01－2015.12，No. 81172967）；
8. 国家自然科学基金面上项目：针对伊马替尼耐药慢性粒细胞白血病的新靶点确证（2015.01－2018.12，No. 81473229）；
9. 国家自然科学基金面上项目：基于光控分子开关酶法制备安全高效低分子量肝素的新策略（2018.01－2021.12，No. 21778076）
10. 国家自然科学基金面上项目：Rapsyn介导的CML干细胞中BCR-ABL ufmylation修饰及其干预策略（2020.01－2023.12，No. 81973386）
1. Chen, Y.J.*, Chen, C. & Wu, X.R. Dicarbonyl reduction by single enzyme for the preparation of chiral diols. Chem. Soc. Rev. 2012, 41(5), 1742-1753.
2. Dacol E.C., Wang S.Z., Chen Y.J.* & Lepique A.P.* The interaction of SET and protein phosphatase 2A as target for cancer therapy. Biochim. Biophys. Acta Rev. Cancer 2021, 1876(1), 188578.
3. Wu, X.R., Jiang, J.P. & Chen, Y.J.* Correlation between intracellular cofactor concentrations and biocatalytic efficiency: coexpression of diketoreductase and glucose dehydrogenase for the preparation of chiral diol for statin drugs. ACS Catal. 2011, 1 (12), 1661-1664.
4. Zhang, J.L., Tao, S.S., Zhang, B.J., Wu, X.R & Chen, Y.J.* Microparticle-based strategy for controlled release of substrate for the biocatalytic preparation of L-homophenylalanine. ACS Catal. 2014, 4(5), 1584-1587.
5. Gu, Y.Y., Wu, X.R., Liu, H. & Chen, Y.J.* Photoswitchable heparinase III for enzymatic preparation of low molecular weight heparin. Org. Lett. 2018, 20(1), 48-51.
6. Yang, J., Chen, Z.M., Liu, N. & Chen, Y.J.* Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. Redox Biol. 2018, 19(1), 158-165.
7. Tan Y.Z., Wang M, & Chen Y.J.* Reprogramming the biosynthesis of precursor peptide to create a selenazole-containing nosiheptide analogue. ACS Synth. Biol. 2022, 11(1), 85-91.
8. Wang K, Chen S.Y., Wu Y, Wang Y, Lu Y., Sun Y.Z. & Chen Y.J.*, The ufmylation modification of ribosomal protein L10 in the development of pancreatic adenocarcinoma. Cell Death Dis. 2023, 14(6), 350-358.
9. Zhang B, Jin W.Z., Zhang Y.Y., Dai Y, Li H.H., Sun Y.Z., Wu X.R.*, Luo J.* & Chen Y.J.*, A type I/type III PKS hybrid generates cinnamomycin A-D. Org. Lett. 2023, 25(15), 2560-2564.
10. Zhao, M.Y., Dai, B.Y., Li, X.D., Zhang, Y.X., Qiao, C., Qin, Y., Li, Z., Li, Q.M., Wang, S.Z.*, Yang, Y.* & Chen, Y.J.*, RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia. eLife, 2023, https://doi.org/10.1101/2023.05.24.542110.
